

# Marroof Alam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11642105/publications.pdf>

Version: 2024-02-01

29  
papers

1,614  
citations

236612

25  
h-index

525886

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2084  
citing authors

#	ARTICLE	IF	CITATIONS
1	MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 205-215.	0.4	167
2	Dependence on the MUC1-C Oncoprotein in Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 806-816.	1.9	144
3	Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. <i>Oncotarget</i> , 2016, 7, 11756-11769.	0.8	144
4	MUC1-C Oncoprotein Promotes STAT3 Activation in an Autoinductive Regulatory Loop. <i>Science Signaling</i> , 2011, 4, ra9.	1.6	84
5	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. <i>Cancer Research</i> , 2016, 76, 1538-1548.	0.4	84
6	MUC1-C Oncoprotein Activates ERK1/2/EBP2 Signaling and Induction of Aldehyde Dehydrogenase 1A1 in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 30892-30903.	1.6	72
7	MUC1-C drives MYC in multiple myeloma. <i>Blood</i> , 2016, 127, 2587-2597.	0.6	71
8	MUC1-C Oncoprotein Induces TCF7L2 Transcription Factor Activation and Promotes Cyclin D1 Expression in Human Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 10703-10713.	1.6	63
9	Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. <i>Oncotarget</i> , 2014, 5, 2622-2634.	0.8	59
10	MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. <i>Oncotarget</i> , 2014, 5, 8893-8905.	0.8	54
11	MUC1-C Induces the LIN28B/LET-7/HMGA2 Axis to Regulate Self-Renewal in NSCLC. <i>Molecular Cancer Research</i> , 2015, 13, 449-460.	1.5	53
12	MUC1-C Oncoprotein Regulates Glycolysis and Pyruvate Kinase m2 Activity in Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e28234.	1.1	53
13	Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. <i>Clinical Cancer Research</i> , 2015, 21, 2338-2347.	3.2	51
14	Development, characterization and efficacy of niosomal diallyl disulfide in treatment of disseminated murine candidiasis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 247-256.	1.7	49
15	Targeting MUC1-C inhibits the AKT-S6K1-eIF4A pathway regulating TICAR translation in colorectal cancer. <i>Molecular Cancer</i> , 2017, 16, 33.	7.9	48
16	The MUC1-C Oncoprotein Binds to the BH3 Domain of the Pro-apoptotic BAX Protein and Blocks BAX Function. <i>Journal of Biological Chemistry</i> , 2012, 287, 20866-20875.	1.6	46
17	MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. <i>Prostate</i> , 2012, 72, 1659-1668.	1.2	46
18	MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, e1338998.	2.1	44

#	ARTICLE	IF	CITATIONS
19	MUC1-C activates EZH2 expression and function in human cancer cells. <i>Scientific Reports</i> , 2017, 7, 7481.	1.6	38
20	Potential of Diallyl Sulfide Bearing pH-Sensitive Liposomes in Chemoprevention Against DMBA-Induced Skin Papilloma. <i>Molecular Medicine</i> , 2007, 13, 443-451.	1.9	36
21	MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. <i>Scientific Reports</i> , 2016, 6, 26643.	1.6	36
22	MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. <i>Molecular Cancer Research</i> , 2016, 14, 1266-1276.	1.5	36
23	Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 13.	7.1	36
24	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 38974-38987.	0.8	36
25	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. <i>Blood</i> , 2015, 126, 354-362.	0.6	31
26	Efficacy of niosomal formulation of diallyl sulfide against experimental candidiasis in Swiss albino mice. <i>Nanomedicine</i> , 2009, 4, 713-724.	1.7	24
27	Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 69237-69249.	0.8	8
28	Use of a Liposomal Delivery System for Herbal-Based Therapeutics (with a Focus on Clove Oil). , 0, , 357-367.		1
29	MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 808-808.	0.6	0